Adicon Holdings Ltd (HKSE:09860) Share Price

Company Profile

Business description
Founded in 2004 and listing on the Hong Kong Exchange in 2023, Adicon is one of the largest independent clinical laboratories in China. In October 2018, private equity Carlyle Group completed its investment in Adicon and has since been the largest single shareholder. Following Carlyle’s investment, Adicon quickly stepped up its footprint. It has a testing portfolio of over 4,000 medical diagnostic tests with 34 self-operated laboratories in 2024, compared with 1,800 items and 21 labs in 2018. Currently, esoteric tests account for nearly 60% of its testing portfolio. Esoteric tests require more specialized technologies and/or equipment.
Contact
No. 208, Zhenzhong Road
West Lake
Zhejiang
Hangzhou
CHN
T: +86 57187779340
https://www.adicon.com.cn
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
5,151

Recommended

These are the most overvalued stocks in Berkshire Hathaway’s portfolio.

Susan Dziubinski | 25 September 2025

With small capitalisation stocks gaining momentum, there are important considerations to determine whether they are right for your portfolio.

Simonelle Mody | 25 September 2025

A more focused business model should benefit the company.

Mark Taylor | 25 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,079.20	17.70	0.20%
CAC 40	7,870.68	75.26	0.97%
DAX 40	23,739.47	204.64	0.87%
Dow JONES (US)	46,247.29	299.97	0.65%
FTSE 100	9,284.83	70.85	0.77%
HKSE	26,128.20	356.48	-1.35%
NASDAQ	22,484.07	99.37	0.44%
Nikkei 225	45,354.99	399.94	-0.87%
NZX 50 Index	13,111.73	42.06	-0.32%
S&P 500	6,643.70	38.98	0.59%
S&P/ASX 200	8,787.70	13.20	0.15%
SSE Composite Index	3,828.11	25.20	-0.65%